3.Longlasting Remission of Primary Hepatic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Achieved by Radiotherapy Alone.
Sang Yun SHIN ; Jin Seok KIM ; Jong Keun LIM ; Jee Sook HAHN ; Woo Ick YANG ; Chang Ok SUH
The Korean Journal of Internal Medicine 2006;21(2):127-131
Primary hepatic lymphoma is a rare disorder representing less than 1% of all extranodal lymphomas. Histological examination of a primary hepatic lymphoma usually reveals a diffuse large B-cell lymphoma; there have been few reports of primary hepatic mucosa-associated lymphoid tissue (MALT) lymphomas. A 67-year-old man was being treated for a duodenal ulcer; while receiving therapy for the ulcer, a liver mass was incidentally found on abdominal ultrasonography. The pathologic diagnosis of the hepatic mass was an extranodal marginal zone B-cell lymphoma of MALT. The patient underwent radiotherapy with a total of 4,140 cGy delivered. The patient achieved complete remission and has been followed for 6 years with no recurrence of the disease. This report reviews the case of a primary hepatic extranodal marginal zone B-cell lymphoma of MALT successfully treated by radiotherapy alone.
Male
;
Lymphoma, Mucosa-Associated Lymphoid Tissue/diagnosis/pathology/*radiotherapy
;
Liver Neoplasms/diagnosis/pathology/*radiotherapy
;
Humans
;
Aged
4.One cases of nasal synovial sarcoma.
Dan WANG ; Xin HE ; Hong ZHENG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2016;30(3):251-253
Synovial sarcoma is a rare tumour found in soft tissue; it is a mesenchymal spindle cell tumour that is not related to the synovial membrane. This tumour has a low incidence, and the most frequent place of occurrence is the lower extremities in young adults. Synovial sarcoma of the head and neck accounts for 3%-5% of sarcomas in this anatomical region. The tumor in the nasal cavity is less than 1%. The treatment of choice for synovial sarcoma of the head and neck is complete surgical excision of the tumour mass followed by adjuvant radiotherapy.
Humans
;
Nasal Cavity
;
pathology
;
Nose Neoplasms
;
diagnosis
;
radiotherapy
;
surgery
;
Paranasal Sinuses
;
pathology
;
Radiotherapy, Adjuvant
;
Sarcoma, Synovial
;
diagnosis
;
radiotherapy
;
surgery
5.Radiotherapy targeting cancer stem cells "awakens" them to induce tumour relapse and metastasis in oral cancer.
Yangfan LIU ; Miao YANG ; Jingjing LUO ; Hongmei ZHOU
International Journal of Oral Science 2020;12(1):19-19
Radiotherapy is one of the most common treatments for oral cancer. However, in the clinic, recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying mechanism remains unclear. Cancer stem cells (CSCs), considered the "seeds" of cancer, have been confirmed to be in a quiescent state in most established tumours, with their innate radioresistance helping them survive more easily when exposed to radiation than differentiated cancer cells. There is increasing evidence that CSCs play an important role in recurrence and metastasis post-radiotherapy in many cancers. However, little is known about how oral CSCs cause tumour recurrence and metastasis post-radiotherapy. In this review article, we will first summarise methods for the identification of oral CSCs and then focus on the characteristics of a CSC subpopulation induced by radiation, hereafter referred to as "awakened" CSCs, to highlight their response to radiotherapy and potential role in tumour recurrence and metastasis post-radiotherapy as well as potential therapeutics targeting CSCs. In addition, we explore potential therapeutic strategies targeting these "awakened" CSCs to solve the serious clinical challenges of recurrence and metastasis in oral cancer after radiotherapy.
Humans
;
Mouth Neoplasms
;
pathology
;
radiotherapy
;
Neoplasm Recurrence, Local
;
radiotherapy
;
Neoplastic Stem Cells
;
pathology
;
radiation effects
;
Radiotherapy
;
methods
;
Recurrence
6.Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer.
Yuming WAN ; Jing HUANG ; Feng XU
Chinese Journal of Lung Cancer 2018;21(5):413-418
A few study has proven that about 90% of local control rates might be benefit from stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), it is reported SBRT associated overall survival and tumor specific survival is comparable with those treated with surgery. SBRT has been accepted as the first line treatment for inoperable patients with peripheral located stage I NSCLC. However, the role of SBRT in centrally located lesions is controversial for potential toxic effects from the adjacent anatomical structure. This paper will review the definition, indication, dose regimens, dose-volume constraints for organs at risk, radiation technology, treatment side effect of centrally located NSCLC treated with SBRT and stereotactic body proton therapy.
Carcinoma, Non-Small-Cell Lung
;
pathology
;
radiotherapy
;
Humans
;
Lung Neoplasms
;
pathology
;
radiotherapy
;
Neoplasm Staging
;
Radiotherapy
;
instrumentation
;
methods
7.Strontium-89 for bone metastases from prostate cancer: an update.
Wei-wei ZHAO ; Peng XIE ; Hou-fu DENG
National Journal of Andrology 2010;16(3):269-272
Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 +/- 4 to 231 +/- 56 cGy/MBq, 2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer, with analgesic effectiveness in 80%.
Bone Neoplasms
;
radiotherapy
;
secondary
;
Humans
;
Male
;
Neoplasm Metastasis
;
Prostatic Neoplasms
;
pathology
;
radiotherapy
;
Strontium Radioisotopes
;
therapeutic use
8.Hypofractionated High-Dose Intensity-Modulated Radiotherapy (60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: A Case Report.
Jaeho CHO ; Gwi Eon KIM ; Koon Ho RHA ; Joong Bae AHN ; Chang Geol LEE ; Chang Ok SUH ; Jinsil SEONG ; Ki Chang KEUM ; Song Ie KIM ; Yoon Hee LEE
Journal of Korean Medical Science 2008;23(4):740-743
A patient with renal cell carcinoma (RCC) developed synchronous bone metastasis with metachronous relapses to the bone and renal fossa. The primary lesion was initially removed surgically, and the metastatic bone lesions and locally recurrent tumours were treated by a high-fractional dose and high-total-dose intensitymodulated radiotherapy (IMRT, 60 Gy at 2.5 Gy per fraction) without significant side effects. All the grossly relapsed tumors underwent complete remission (CR) within a short time after IMRT. To date, CR has been maintained for more than two years. This case study reports the successful treatment of radioresistant RCC using a new scheme that involves a fractionation regimen with a high precision radiotherapy.
Carcinoma, Renal Cell/pathology/*radiotherapy
;
Dose Fractionation
;
Female
;
Humans
;
Kidney Neoplasms/pathology/*radiotherapy
;
Middle Aged
;
Neoplasm Recurrence, Local/pathology/*radiotherapy
;
Radiotherapy, Intensity-Modulated
9.A Dosimetric Comparison between Conventional Fractionated and Hypofractionated Image-guided Radiation Therapies for Localized Prostate Cancer.
Ming LI ; Gao-Feng LI ; Xiu-Yu HOU ; Hong GAO ; Yong-Gang XU ; Ting ZHAO
Chinese Medical Journal 2016;129(12):1447-1454
BACKGROUNDImage-guided radiation therapy (IGRT) is the preferred method for curative treatment of localized prostate cancer, which could improve disease outcome and reduce normal tissue toxicity reaction. IGRT using cone-beam computed tomography (CBCT) in combination with volumetric-modulated arc therapy (VMAT) potentially allows smaller treatment margins and dose escalation to the prostate. The aim of this study was to compare the difference of dosimetric diffusion in conventional IGRT using 7-field, step-and-shoot intensity-modulated radiation therapy (IMRT) and hypofractionated IGRT using VMAT for patients with localized prostate cancer.
METHODSWe studied 24 patients who received 78 Gy in 39 daily fractions or 70 Gy in 28 daily fractions to their prostate with/without the seminal vesicles using IMRT (n = 12) or VMAT (n = 12) for prostate cancer between November 2013 and October 2015. Image guidance was performed using kilovoltage CBCT scans equipped on the linear accelerator. Offline planning was performed using the daily treatment images registered with simulation computed tomography (CT) images. A total of 212 IMRT plans in conventional cohort and 292 VMAT plans in hypofractionated cohort were enrolled in the study. Dose distributions were recalculated on CBCT images registered with the planning CT scanner.
RESULTSCompared with 7-field, step-and-shoot IMRT, VMAT plans resulted in improved planning target volume (PTV) D95% (7663.17 ± 69.57 cGy vs. 7789.17 ± 131.76 cGy, P < 0.001). VMAT reduced the rectal D25 (P < 0.001), D35 (P < 0.001), and D50 (P < 0.001), bladder V50 (P < 0.001), D25 (P = 0.002), D35 (P = 0.028), and D50 (P = 0.029). However, VMAT did not statistically significantly reduce the rectal V50, compared with 7-field, step-and-shoot IMRT (25.02 ± 5.54% vs. 27.43 ± 8.79%, P = 0.087).
CONCLUSIONSTo deliver the hypofractionated radiotherapy in prostate cancer, VMAT significantly increased PTV D95% dose and decreased the dose of radiation delivered to adjacent normal tissues comparing to 7-field, step-and-shoot IMRT. Daily online image-guidance and better management of bladder and rectum could make a more precise treatment delivery.
Aged ; Aged, 80 and over ; Humans ; Male ; Prostate ; pathology ; radiation effects ; Prostatic Neoplasms ; pathology ; radiotherapy ; Radiotherapy Dosage ; Radiotherapy, Image-Guided ; methods ; Radiotherapy, Intensity-Modulated ; methods ; Retrospective Studies
10.Intensity modulated radiation therapy for 49 patients with recurrent nasopharyngeal carcinoma.
Tai-xiang LU ; Chong ZHAO ; Fei HAN ; Ying HUANG ; Xiao-wu DENG ; Li-xia LU ; Zhi-fan ZENG ; Shao-min HUANG ; Cheng-guang LIN ; Nian-ji CUI
Chinese Journal of Oncology 2003;25(4):386-389
OBJECTIVETo evaluate the feasibility, toxicity and tumor control of intensity modulated radiation therapy (IMRT) for recurrent nasopharyngeal carcinoma.
METHODSFourty-nine patients (Karnofsky performance status (KPS) >or= 80) with local-regional recurrence in the nasopharynx were treated with full course IMRT. Three patients with cervical lymph node metastasis (N1 2 and N3 1) were further supplemented with 5 to 6 courses of chemotherapy (Cisplatin + 5-Fu) after IMRT.
RESULTSThe results of treatment plan showed that the mean dose of covering gross tumor volume (GTV) (D(95)) in the nasopharynx was 68.09 Gy and the mean volume of GTV (V(95)) receiving the 95% dose was 98.46%. The mean dose of GTV, clinical target volume CTV1 and CTV2 in the targets were 71.40 Gy, 63.63 Gy and 59.81 Gy. The median follow-up time was 9 months (range 3 to 16 months). The local-regional progression-free survival was 100% with local-regional residual disease in 3 (6.1%) cases but was complicated with nasopharyngeal mucosa necrosis in 14 (28.6%) cases after IMRT.
CONCLUSIONIntensity modulated radiation therapy, as a re-treatment option for recurrent nasopharyngeal carcinoma, is able to improve the tumor target coverage and spare the adjacent critical structures. As high dose IMRT can result in radio-necrosis of nasopharyngeal mucosa, the prescription dose of GTV should be suitably decreased to 60 - 65 Gy.
Adult ; Aged ; Carcinoma, Squamous Cell ; pathology ; radiotherapy ; Female ; Follow-Up Studies ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Nasopharyngeal Neoplasms ; pathology ; radiotherapy ; Neoplasm Recurrence, Local ; radiotherapy ; Neoplasm Staging ; Radiation Injuries ; pathology ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted ; Radiotherapy, Conformal ; methods